Ignite Creation Date:
2024-05-06 @ 8:11 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06287463
Status:
RECRUITING
Last Update Posted:
2024-06-24
First Post:
2024-02-23
Brief Title:
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase MAPK Pathway
Sponsor:
Deciphera Pharmaceuticals LLC
Organization:
Deciphera Pharmaceuticals LLC
Study Overview
Official Title:
A Master Protocol for the Multi-Cohort Open-Label Phase 12 Study of DCC-3084 as Monotherapy and in Combination With Other Antitumor Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter Phase 12 clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers Module A will enroll participants with solid tumors Additional modules exploring other cancers may be added to the master protocol at a later date Each module will be conducted in 2 parts Part 1 Dose Escalation and Part 2 Dose Expansion
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None